The short answer: systemic estrogen therapy is the most effective treatment for menopausal hot flashes, cutting moderate-to-severe episodes by about 75–90%. If hormones are unsuitable or unwanted, fezolinetant (Veozah) is the strongest hormone-free prescription option at roughly 60–65%, followed by venlafaxine, low-dose paroxetine, gabapentin, and oxybutynin. Most first relief arrives in 1–2 weeks, with full effect by about 12 weeks. Over-the-counter supplements, including black cohosh, do not reliably beat placebo.
About 75–80% of women experience hot flashes during the menopause transition, and in the SWAN cohort they lasted a median of 7.4 years — more than ten years for women whose flashes started before their periods stopped. Despite that, most women are never offered a guideline-concordant treatment. This guide exists to close that gap: it lays out the mechanism, compares every option on trial evidence rather than marketing, and tells you honestly what does not work.
Hot flash severity quiz
Eight questions, structured like the interference scales used in vasomotor treatment trials. You get a 0–100 score, a severity band, and the guideline-concordant options that match it. No email required.
Treatment comparison table
Fourteen options, with the reduction in moderate-to-severe hot flash frequency reported in randomized trials, the placebo-subtracted benefit where it was published, and the evidence grade. Sourced, not vibes.
| Treatment | Class | Reduction in flashes | vs placebo | First relief | Evidence | Notes |
|---|---|---|---|---|---|---|
| Transdermal estradiol (patch/gel)Prescription | Hormonal | 75–90% | ~60 pp | 1–2 wksfull effect ~12 wks | Strong (RCT, guideline first-line) | Most effective option for moderate-to-severe vasomotor symptoms. Lower VTE risk than oral. Requires a progestogen if you have a uterus.Source: The Menopause Society 2023 nonhormone position statement; 2022 HT position statement |
| Oral estradiolPrescription | Hormonal | 75–90% | ~60 pp | 1–3 wksfull effect ~12 wks | Strong (RCT, guideline first-line) | Equally effective as transdermal but with first-pass hepatic effects — higher VTE and gallbladder risk. Reasonable when patches are not tolerated.Source: Endocrine Society Clinical Practice Guideline, postmenopausal HT |
| Micronized progesterone 300 mgPrescription | Hormonal | ~55% | ~20 pp | 2–4 wksfull effect ~12 wks | Moderate (RCT) | Works as a standalone vasomotor treatment when estrogen is unsuitable, and improves sleep quality. At 100–200 mg it is used for endometrial protection alongside estradiol.Source: Hitchcock & Prior, Menopause 2012 (RCT of oral micronized progesterone for VMS) |
| Fezolinetant (Veozah) 45 mgPrescription | Neurokinin | ~60–65% | ~25 pp | 1 wkfull effect ~12 wks | Strong (RCT, guideline first-line) | Hormone-free NK3-receptor antagonist. Meaningful separation from placebo by week 1. Requires baseline and periodic liver enzyme monitoring.Source: SKYLIGHT 1 and SKYLIGHT 2 randomized trials, Lancet / Obstet Gynecol 2023 |
| ElinzanetantPrescription | Neurokinin | ~60–70% | ~25 pp | 1–2 wksfull effect ~12 wks | Moderate (RCT) | Dual NK1/NK3 antagonist with trial-reported benefit on sleep disturbance as well as flash frequency. Availability varies — confirm current status with your clinician.Source: OASIS 1–3 randomized trials, JAMA 2024 |
| Paroxetine mesylate 7.5 mg (Brisdelle)Prescription | Non-hormonal Rx | ~40–45% | ~10 pp | 1–4 wksfull effect ~12 wks | Strong (RCT, guideline first-line) | The only FDA-approved non-hormonal SSRI dose for vasomotor symptoms. Avoid with tamoxifen (CYP2D6 inhibition).Source: The Menopause Society 2023 nonhormone therapy position statement |
| Venlafaxine ER 75 mgPrescription | Non-hormonal Rx | ~40–50% | ~15 pp | 1–3 wksfull effect ~8 wks | Strong (RCT, guideline first-line) | Head-to-head MsFLASH trial showed low-dose estradiol modestly better, but venlafaxine was close and is safe after breast cancer.Source: Joffe et al., MsFLASH Network, JAMA Intern Med 2014 |
| Gabapentin 300–900 mg nightlyPrescription | Non-hormonal Rx | ~45% | ~20 pp | 1–2 wksfull effect ~8 wks | Moderate (RCT) | Best choice when night sweats dominate — dose at bedtime and the sedation becomes a feature rather than a side effect.Source: The Menopause Society 2023 nonhormone therapy position statement |
| Oxybutynin 2.5–5 mg twice dailyPrescription | Non-hormonal Rx | ~60% | ~25 pp | 1–2 wksfull effect ~6 wks | Moderate (RCT) | Strong effect size but anticholinergic burden — generally avoided long term in older adults given cognitive-risk signals.Source: Leon-Ferre et al., ACCRU randomized trial, 2020 |
| ClonidinePrescription | Non-hormonal Rx | ~30–35% | ~10 pp | 1–4 wksfull effect ~8 wks | Limited | Downgraded in current guidelines — modest benefit and a poor tolerability profile compared with newer options.Source: The Menopause Society 2023 nonhormone therapy position statement |
| Cognitive behavioral therapy (CBT-Meno)No prescription needed | Behavioral | Frequency largely unchanged; bother down ~50% | Recommended | 4–6 wksfull effect ~12 wks | Strong (RCT, guideline first-line) | Does not reliably reduce how often flashes happen — it substantially reduces how much they interfere with your life and sleep. Guideline-recommended.Source: The Menopause Society 2023 nonhormone therapy position statement |
| Clinical hypnosisNo prescription needed | Behavioral | ~50–70% (self-reported) | ~30 pp | 3–5 wksfull effect ~12 wks | Moderate (RCT) | Guideline-recommended non-hormonal option. Access is the limiting factor rather than efficacy.Source: Elkins et al., Menopause 2013 |
| Black cohoshNo prescription needed | Supplement | Not separable from placebo | No consistent benefit | 4–12 wksfull effect ~12 wks | Insufficient | Trials are heterogeneous and the pooled effect does not reliably beat placebo. Rare hepatotoxicity reports. Kindr does not sell or recommend it as a treatment.Source: Cochrane review, black cohosh for menopausal symptoms; Menopause Society 2023 |
| Soy isoflavones / S-equolNo prescription needed | Supplement | ~10–20% | Small, inconsistent | 6–12 wksfull effect ~12 wks | Limited | Modest benefit in some meta-analyses, largely in equol producers. Reasonable as diet, not as a substitute for treatment when symptoms are severe.Source: Franco et al., JAMA 2016 (plant-based therapies meta-analysis) |
When each treatment starts working
The single most common reason women abandon a treatment is stopping before it has had time to work. The bar shows the window in which trials report first noticeable relief; the marker shows full effect.
- Oxybutynin 2.5–5 mg twice dailyfirst relief wks 1–2 · full ~wk 6
- Venlafaxine ER 75 mgfirst relief wks 1–3 · full ~wk 8
- Gabapentin 300–900 mg nightlyfirst relief wks 1–2 · full ~wk 8
- Clonidinefirst relief wks 1–4 · full ~wk 8
- Transdermal estradiol (patch/gel)first relief wks 1–2 · full ~wk 12
- Oral estradiolfirst relief wks 1–3 · full ~wk 12
- Fezolinetant (Veozah) 45 mgfirst relief wk 1 · full ~wk 12
- Elinzanetantfirst relief wks 1–2 · full ~wk 12
- Paroxetine mesylate 7.5 mg (Brisdelle)first relief wks 1–4 · full ~wk 12
- Micronized progesterone 300 mgfirst relief wks 2–4 · full ~wk 12
- Clinical hypnosisfirst relief wks 3–5 · full ~wk 12
- Cognitive behavioral therapy (CBT-Meno)first relief wks 4–6 · full ~wk 12
Side-effect comparison
Efficacy is only half the decision. These are the side effects most often reported in the trials for each option, plus the monitoring that goes with it.
| Treatment | Most reported side effects | Monitoring |
|---|---|---|
| Transdermal estradiol (patch/gel) |
| Symptom and bleeding review at 3 months, then annually; BP and risk factors |
| Oral estradiol |
| Symptom and bleeding review at 3 months, then annually; BP and risk factors |
| Micronized progesterone 300 mg |
| Symptom and bleeding review at 3 months, then annually; BP and risk factors |
| Fezolinetant (Veozah) 45 mg |
| Liver enzymes at baseline, then periodically |
| Elinzanetant |
| Liver enzymes at baseline, then periodically |
| Paroxetine mesylate 7.5 mg (Brisdelle) |
| Tolerability review at 4 weeks; BP for venlafaxine |
| Venlafaxine ER 75 mg |
| Tolerability review at 4 weeks; BP for venlafaxine |
| Gabapentin 300–900 mg nightly |
| Tolerability review at 4 weeks; BP for venlafaxine |
| Oxybutynin 2.5–5 mg twice daily |
| Tolerability review at 4 weeks; BP for venlafaxine |
| Clonidine |
| Tolerability review at 4 weeks; BP for venlafaxine |
| Cognitive behavioral therapy (CBT-Meno) |
| None required |
| Clinical hypnosis |
| None required |
| Black cohosh |
| None required |
| Soy isoflavones / S-equol |
| None required |
Why hot flashes happen
A hot flash is a thermoregulatory event, not a hormonal "surge". As estradiol falls, a cluster of neurons in the hypothalamus — the KNDy neurons, which co-express kisspeptin, neurokinin B, and dynorphin — become hypertrophied and hyperactive. Their signalling narrows the thermoneutral zone, the internal temperature range your body tolerates without sweating or shivering. Inside a normal zone a 0.4 °C rise is unremarkable; inside a narrowed zone it trips a full heat-dissipation response: peripheral vasodilation, flushing, sweating, then a chill as you overshoot.
This mechanism explains three things patients notice and most articles skip. It explains why blocking neurokinin B signalling works without any hormone at all — the entire premise of fezolinetant and elinzanetant. It explains why nights are worse: core temperature drops overnight and the tolerance window narrows further. And it explains why alcohol, caffeine, spicy food, and a warm room act as triggers rather than causes — they nudge core temperature or vasodilation, and a narrowed zone does the rest.
Choosing a treatment
If you have no contraindication to hormones
Transdermal estradiol is the usual starting point: highest efficacy, lower venous thromboembolism risk than oral, and easy dose titration. Add micronized progesterone if you have a uterus — it protects the endometrium and often improves sleep as a bonus. Read the estrogen treatment guide and the progesterone guide.
If hormones are not an option
After breast cancer, with a history of estrogen-sensitive tumor, active VTE, or simple preference, the hormone-free path is genuinely effective now. Fezolinetant separates from placebo in week one; venlafaxine came close to low-dose estradiol in the MsFLASH head-to-head. See Veozah and non-hormonal treatment.
If your symptoms are mostly nocturnal
Night-dominant symptoms respond to a different sequencing: bedtime-dosed gabapentin or micronized progesterone often beats a daytime-focused regimen, and sleep needs treating in its own right once flashes are controlled. See night sweats.
What we will not recommend
- Compounded hormone pellets — unpredictable, supra-physiologic exposure with no FDA oversight.
- Supplement stacks marketed as hormone alternatives. Kindr does not sell supplements as hot flash treatment.
- Unmonitored testosterone for vasomotor symptoms — it is not a hot flash treatment.
Our full standards are published on the clinical governance page.
Original Kindr data
Two datasets, both free to cite with attribution to Kindr Health: a live aggregate of anonymous severity-quiz submissions, and our synthesis of the randomized vasomotor trial literature.
1. The Kindr Hot Flash Index (live)
Aggregated from de-identified severity-quiz submissions on this page. No names, no emails, no individual records are exposed — only the summary statistics below.
Sample size
0
Median flashes/day
—
Median nights woken/week
—
Mean severity score
—
Moderate or worse
—
On no treatment
—
This index is newly opened and the sample is still small — read the numbers as provisional until n ≥ 100. Add your answers to strengthen it.
2. Randomized evidence synthesis
Every major randomized trial and cohort behind the treatment table above, in one place — intervention, comparator, endpoint, and result.
| Trial | Year | n | Intervention | Comparator | Endpoint | Result | Citation |
|---|---|---|---|---|---|---|---|
| SKYLIGHT 1 | 2023 | 527 | Fezolinetant 30/45 mg | Placebo | Daily moderate-to-severe VMS frequency, wk 12 | −2.4 episodes/day vs placebo at 45 mg | Lancet 2023;401:1091 |
| SKYLIGHT 2 | 2023 | 501 | Fezolinetant 30/45 mg | Placebo | VMS frequency and severity, wk 12 | Significant reduction from wk 1, sustained to wk 52 | Obstet Gynecol 2023;141:737 |
| OASIS 1 & 2 | 2024 | 796 | Elinzanetant 120 mg | Placebo | VMS frequency, wk 12 + sleep disturbance | Reduced VMS and improved sleep-disturbance scores | JAMA 2024;332:1343 |
| MsFLASH 03 | 2014 | 339 | Low-dose oral estradiol 0.5 mg | Venlafaxine ER 75 mg / placebo | VMS frequency, wk 8 | Estradiol −2.8, venlafaxine −2.3, placebo −1.8 per day | JAMA Intern Med 2014;174:1058 |
| ACCRU oxybutynin | 2020 | 150 | Oxybutynin 2.5–5 mg BID | Placebo | Hot flash score, wk 6 | Significant reduction in frequency and score | J Clin Oncol 2020;38:1815 |
| Progesterone VMS RCT | 2012 | 133 | Micronized progesterone 300 mg | Placebo | VMS score, wk 12 | −56% vs −32% placebo | Menopause 2012;19:886 |
| MENOS2 (CBT) | 2012 | 140 | Group CBT | Usual care | Hot flash problem-rating | Large reduction in bother; frequency little changed | Menopause 2012;19:749 |
| SWAN cohort | 2015 | 1,449 | Observational | — | Total VMS duration | Median 7.4 years; 10+ years when onset is premenopausal | JAMA Intern Med 2015;175:531 |
| Cochrane black cohosh | 2012 | 1,400 | Black cohosh | Placebo | VMS frequency | No consistent benefit over placebo | Cochrane Database Syst Rev 2012;9:CD007244 |
| Plant-based therapies meta-analysis | 2016 | 6,653 | Phytoestrogens | Placebo | VMS frequency | Modest reduction, high heterogeneity | JAMA 2016;315:2554 |
Citing this? Use “Kindr Health, Hot Flash Treatment Evidence Synthesis (2026)”. More datasets on our open data hub.
Where treatment is available
Kindr clinicians are licensed in all 50 states and Washington, DC. Search your state or city to see local prescribing details and climate-specific guidance.
51 of 51 jurisdictions shown
Know your score and want a plan? A Kindr Health clinician will review your history and prescribe the option that fits — hormonal or hormone-free.
Start your visit →Not ready? Ask Dot, our free AI menopause companion.
Frequently asked questions
What is the most effective treatment for hot flashes?
Systemic estrogen therapy is the most effective treatment, reducing moderate-to-severe hot flash frequency by roughly 75–90% in randomized trials. For women who cannot or prefer not to take hormones, fezolinetant (Veozah) is the strongest hormone-free prescription option, with about a 60–65% reduction, followed by SNRIs, low-dose paroxetine, gabapentin, and oxybutynin.
How quickly does treatment for hot flashes work?
Fezolinetant separates from placebo within the first week. Transdermal estradiol usually produces noticeable improvement in 1–2 weeks and full effect by about 12 weeks. SSRIs and SNRIs take 1–4 weeks. CBT takes 4–6 weeks and works by reducing how much flashes bother you rather than how often they occur.
How long do hot flashes last overall?
In the SWAN cohort the median total duration of vasomotor symptoms was 7.4 years. Women whose flashes begin before their periods stop average more than 10 years, while those whose flashes start after menopause average closer to 3–4 years.
Are hot flashes dangerous?
Hot flashes themselves are not dangerous, but frequent and persistent vasomotor symptoms are associated in cohort studies with poorer sleep, higher cardiovascular risk markers, and lower quality-of-life scores. That association is a reason to treat symptoms, not to panic about them.
Can I treat hot flashes without hormones?
Yes. Fezolinetant, elinzanetant, venlafaxine, paroxetine mesylate 7.5 mg, gabapentin, oxybutynin, CBT, and clinical hypnosis all have randomized-trial support and are recommended in current non-hormone guidance. Most over-the-counter supplements, including black cohosh, do not reliably outperform placebo.
Do supplements work for hot flashes?
Mostly no. Pooled trial data for black cohosh, evening primrose oil, and most botanical blends show no consistent advantage over placebo. Soy isoflavones show a small effect in some analyses, largely in women who produce equol. Kindr does not sell supplements as a hot flash treatment.
Why do hot flashes happen at night more than during the day?
Core body temperature naturally falls at night, and the thermoregulatory threshold narrows during sleep, so a small internal temperature rise is more likely to trigger a sweating response. Alcohol in the evening and a warm bedroom both make nocturnal episodes more likely.
Can I get treated for hot flashes online?
Yes. Kindr clinicians are licensed in all 50 states and prescribe FDA-approved hormonal and non-hormonal treatment after a clinical review, with follow-up built into the plan.
The hot flashes hub
Nineteen connected resources: mechanism, every treatment class, tools, research, and care. Start anywhere.
Continue across the Kindr entity graph
Related evidence, peptides, and clinical tools on the same topic.
- Hot flashes & night sweats: evidenceJournal
- Is HRT safe?Journal
- Fezolinetant (non-hormonal)Medication
- When to start HRTJournal
- EstradiolMedication
- Menopause HRT serviceMedication
Sources
- The Menopause Society. 2023 Nonhormone Therapy Position Statement.
- The Menopause Society. 2022 Hormone Therapy Position Statement.
- Avis NE et al. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN). JAMA Intern Med 2015.
- Johnson KA et al. SKYLIGHT 2: fezolinetant for vasomotor symptoms. Obstet Gynecol 2023.
- Lederman S et al. SKYLIGHT 1. Lancet 2023.
- Joffe H et al. Low-dose estradiol and venlafaxine for vasomotor symptoms (MsFLASH). JAMA Intern Med 2014.
- ACOG Practice Bulletin: Management of Menopausal Symptoms.
Educational content only — not a substitute for professional medical advice, diagnosis, or treatment. The severity quiz is a screening aid, not a diagnosis. Reviewed by the Kindr Health clinical team · Last reviewed 2026-07-26.